ValuEngine Downgrades Viveve Medical (VIVE) to Strong Sell
Viveve Medical (NASDAQ:VIVE) was downgraded by ValuEngine from a “sell” rating to a “strong sell” rating in a research note issued on Friday.
A number of other equities research analysts have also recently weighed in on the stock. Mizuho assumed coverage on shares of Viveve Medical in a research report on Thursday, November 16th. They set a “buy” rating and a $10.00 price target for the company. Cowen set a $11.00 price target on shares of Viveve Medical and gave the company a “buy” rating in a research report on Monday, October 23rd. Finally, Maxim Group reissued a “buy” rating and issued a $11.00 price objective on shares of Viveve Medical in a research note on Friday, August 11th. One investment analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. Viveve Medical has an average rating of “Buy” and an average target price of $10.40.
Shares of Viveve Medical (VIVE) traded up $0.09 on Friday, hitting $5.10. 156,741 shares of the company’s stock were exchanged, compared to its average volume of 183,584. Viveve Medical has a 1-year low of $3.75 and a 1-year high of $11.16. The company has a quick ratio of 3.63, a current ratio of 3.89 and a debt-to-equity ratio of 2.72.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Neuberger Berman Group LLC purchased a new position in Viveve Medical in the third quarter worth approximately $419,000. Granahan Investment Management Inc. MA lifted its stake in Viveve Medical by 32.6% in the third quarter. Granahan Investment Management Inc. MA now owns 102,147 shares of the company’s stock worth $535,000 after acquiring an additional 25,097 shares during the last quarter. RTW Investments LP lifted its stake in Viveve Medical by 18.8% in the third quarter. RTW Investments LP now owns 1,473,028 shares of the company’s stock worth $7,719,000 after acquiring an additional 233,585 shares during the last quarter. ING Groep NV lifted its stake in Viveve Medical by 93.7% in the third quarter. ING Groep NV now owns 325,000 shares of the company’s stock worth $1,703,000 after acquiring an additional 157,200 shares during the last quarter. Finally, California State Teachers Retirement System purchased a new position in Viveve Medical in the second quarter worth approximately $190,000. 67.02% of the stock is owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY WARNING: “ValuEngine Downgrades Viveve Medical (VIVE) to Strong Sell” was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/12/01/valuengine-downgrades-viveve-medical-vive-to-strong-sell.html.
About Viveve Medical
Viveve Medical, Inc designs, develops, manufactures and markets a medical device, Geneveve, for the non-invasive treatment of vaginal laxity, for improved sexual function, and for vaginal rejuvenation. The Company’s, Geneveve, is a non-invasive solution for vaginal laxity, which includes three components: the Viveve System (a radio frequency (RF), generator housed in a table-top console), a reusable handpiece and a single-use treatment tip, as well as several other consumable accessories.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Viveve Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viveve Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.